Video Library

CAR T-cell therapy is a new treatment option for lymphoma patients whose disease has been resistant to standard chemotherapy. This presentation describes what’s involved in going through CAR T-cell therapy, the CAR T-cell products currently approved by the FDA, and the short- and long-term side effects of treatment.

La terapia de células CAR T es una nueva opción de tratamiento para pacientes con leucemia linfoblástica aguda, algunos linfomas y mieloma múltiple que no han respondido a terapias anteriores. Esta presentación describe cómo funciona la terapia de células CAR T, sus riesgos y efectos secundarios, y cómo estos pueden manejarse de manera efectiva.

The age of patients undergoing a stem cell transplant or CAR T-cell therapy is increasing, but older patients are often not as fit as younger adults. Transplant and CAR T-cell therapies can be modified to increase the likelihood of success for old adults.

Bone marrow transplant survivors have an increased risk of developing a second or “secondary” cancer later in life. This video discusses risk factors for developing a secondary cancer, cancers most frequently seen after transplant and monitoring and testing that should be done periodically to catch second cancers early when they are easiest to treat. (Throughout the talk, bone marrow transplant refers both to bone marrow transplants and stem cell transplants, as well as cord blood transplants.)

A variety of skin problems are common after a bone marrow or stem cell transplant including infections, rashes, hair loss, lesions and skin cancer. This video discusses both malignant and non-malignant skin problems, who is at risk for developing these problems, recommended skin care after transplant, and testing to prevent or diagnose skin problems early.

This presentation reviews some of the short- and long-term cardiovascular toxicities that can develop after stem cell transplantation. It describes strategies that patients and their physicians can use to reduce the risk of developing cardiovascular problems after transplant.

Several types of infection can occur after a stem cell or bone marrow transplant and can complicate recovery for patients. This presentation describes the infection risks during the posttransplant period, therapies to treat them, and some measures to prevent them.

Distintos tipos de infecciones pueden ocurrir después de un trasplante y pueden complicar la recuperación de los pacientes. Esta presentación describe los riesgos de infecciones después de un trasplante, las terapias para tratarlas, y algunas medidas para prevenirlas.

Graft-versus-host-disease (GVHD) is a common challenge for patients who undergo a stem cell transplant using cells from a donor (an allogeneic transplant). It can be mild, moderate or severe. This presentation reviews the types of GVHD, the organs most often affected, common symptoms, and traditional as well as newer therapies for treating GVHD.

La Enfermedad de Injerto contra Huésped (EICH) puede ser aguda o crónica. Este taller explica la diferencia entre ambas, los factores de riesgo, su incidencia, cuáles son los síntomas, cuándo comienzan y cuánto duran. También explica las terapias para el tratamiento de la EICH aguda y crónica, así como los efectos secundarios de esos medicamentos.

Several new therapies have recently been approved to prevent and treat graft-versus-host disease (GVHD) and more are being studied. The new therapies are more effective than the standard GVHD therapies and should result in a lower incidence of GVHD with fewer toxicities for patients, going forward.

Este video informa acerca de los avances en la prevención y el tratamiento de la enfermedad de injerto contra huésped aguda y crónica, así como sobre las drogas que han sido aprobadas por el FDA y algunos ensayos clínicos que se están desarrollando actualmente.